Non-vitamin K versus vitamin K antagonist oral anticoagulants in surgical mitral valve repair or bioprosthetic valve replacement in the first three months after surgery.

Autor:	Costa H; Department of Cardiology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal. Electronic address: hugoalexcosta@sapo.pt., Custódio P; Department of Cardiology, Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal., Baptista Gonçalves R; School of Medicine, University of Liverpool, Liverpool, United Kingdom., Lamares Magro P; Department of Cardio-thoracic Surgery, Hospital de Santa Cruz, Carnaxide, Portugal., Sousa Uva M; Department of Cardio-thoracic Surgery, Hospital de Santa Cruz, Carnaxide, Portugal.
Jazyk:	English; Portuguese
Zdroj:	Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology [Rev Port Cardiol] 2024 Sep; Vol. 43 (9), pp. 501-509. Date of Electronic Publication: 2024 Jun 28.
DOI:	10.1016/j.repc.2024.02.013
Abstrakt:	Introduction and Objectives: Oral anticoagulation (OAC) with non-vitamin K antagonist oral anticoagulants (NOACs) after surgical mitral valve repair (MVR) or bioprosthetic valve replacement (BVR) in mitral position remains a controversial topic among the cardiovascular community, in particular in the early postoperative period. This study aimed to evaluate the efficacy and safety of NOACs in the first three months after MVR or mitral BVR compared to vitamin K antagonists (VKAs). Methods: This was a single-center retrospective study with prospectively collected peri-intervention outcomes between 2020 and 2021. Records were retrieved and all participants were contacted by telephone. Patients were divided into groups according to OAC strategy. The primary outcome was a composite of death, rehospitalization, myocardial infarction, stroke or transient ischemic attack, systemic embolism, mitral thrombosis, or bleeding during the first three months after surgery. Results: A total of 148 patients were enrolled, with a mean age of 65.5±12.2 years, 56.8% male. On discharge, 98 (66.2%) patients were on VKAs and 50 (33.8%) were on DOACs for at least three months. The primary outcome occurred in 22 (22.4%) patients in the VKA group and in three (6%) in the NOAC group (p=0.012), mainly driven by more bleeding events in the former. Independent predictors of the primary outcome were smoking (p=0.028) and OAC with VKAs at discharge, the latter predicting three times more events (p=0.046, OR 3.72, 95% CI 1.02-13.5). Conclusions: NOACs were associated with fewer events, supporting their efficacy and safety during the first three months after surgical MVR or mitral BVR. (Copyright © 2024 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu